Jane Boggs, MD
Clinical Neurophysiology · Winston Salem, NCNPI 1245200294
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 23.1% of the total. Reporting peaked in 2019 at $296 and has fallen 80.9% since, to $57 in 2025.
Across 7 payments — averaging $79.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$128
- UCB, Inc.$119
- SK Life Science, Inc.$84
- Zimmer Biomet$57
- Neuropace, Inc.$57
- Acadia Pharmaceuticals Inc$57
- plus $54 from 1 others
Across 25 payments — averaging $5209.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$118K
- UCB SA$12K
What the payments were for
- Food & beverage$555100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 1 | $128 |
| UCB, Inc. | 1 | $119 |
| SK Life Science, Inc. | 1 | $84 |
| Zimmer Biomet | 1 | $57 |
| Neuropace, Inc. | 1 | $57 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
| Medtronic | 1 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$128
How this compares
Too few clinical neurophysiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LamictalLamotrigine | 48 | $82,734 |
| KeppraLevetiracetam | 33 | $61,155 |
| XcopriCenobamate | 44 | $59,849 |
| EpidiolexCannabidiol (Cbd) | 18 | $51,038 |
| Keppra XrLevetiracetam | 13 | $20,706 |
| Lamotrigine ErLamotrigine | 23 | $10,396 |
| NayzilamMidazolam | 13 | $8,064 |
| Levetiracetam | 100 | $7,258 |
| Clobazam | 93 | $6,802 |
| Lacosamide | 46 | $5,828 |
| Oxcarbazepine | 56 | $3,740 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $3,712 |
| Levetiracetam ErLevetiracetam | 29 | $3,430 |
| Zonisamide | 69 | $2,418 |
| Phenobarbital | 33 | $2,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $84 | $59,84944 claims |
| UCB, Inc.Nayzilam | $119 | $8,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Winston Salem
- James CaressWinston Salem$24K
- Muhammad ZafarDurham$144K
- Christa SwisherCharlotte$39K
- Matthew LuedkeDurham$7K
- Vishal MandgeDurham$4K
- Adrian HadionoConcord$2K
- Christopher ConnellyConcord$431
- Jennifer ZuroskyCharlotte$404
- Betty StewartHendersonville$54
- Prabhu EmmadyConcord$54
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.